Palmos Alish B, Watson Stuart, Hughes Tom, Finkelmeyer Andreas, McAllister-Williams R Hamish, Ferrier Nicol, Anderson Ian M, Nair Rajesh, Young Allan H, Strawbridge Rebecca, Cleare Anthony J, Chung Raymond, Frissa Souci, Goodwin Laura, Hotopf Matthew, Hatch Stephani L, Wang Hong, Collier David A, Thuret Sandrine, Breen Gerome, Powell Timothy R
King's College London,Social,Genetic and Developmental Psychiatry Centre,UK.
Academic Clinical Senior Lecturer, Institute of Neuroscience, Wolfson Research Centre,Newcastle University,Campus for Ageing and Vitality;andNorthumberland Tyne and Wear NHS Foundation Trust,UK.
BJPsych Open. 2019 Jan;5(1):e3. doi: 10.1192/bjo.2018.80.
Childhood maltreatment is one of the strongest predictors of adulthood depression and alterations to circulating levels of inflammatory markers is one putative mechanism mediating risk or resilience.AimsTo determine the effects of childhood maltreatment on circulating levels of 41 inflammatory markers in healthy individuals and those with a major depressive disorder (MDD) diagnosis.
We investigated the association of childhood maltreatment with levels of 41 inflammatory markers in two groups, 164 patients with MDD and 301 controls, using multiplex electrochemiluminescence methods applied to blood serum.
Childhood maltreatment was not associated with altered inflammatory markers in either group after multiple testing correction. Body mass index (BMI) exerted strong effects on interleukin-6 and C-reactive protein levels in those with MDD.
Childhood maltreatment did not exert effects on inflammatory marker levels in either the participants with MDD or the control group in our study. Our results instead highlight the more pertinent influence of BMI.Declaration of interestD.A.C. and H.W. work for Eli Lilly Inc. R.N. has received speaker fees from Sunovion, Jansen and Lundbeck. G.B. has received consultancy fees and funding from Eli Lilly. R.H.M.-W. has received consultancy fees or has a financial relationship with AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Ferrer, Janssen-Cilag, Lundbeck, MyTomorrows, Otsuka, Pfizer, Pulse, Roche, Servier, SPIMACO and Sunovian. I.M.A. has received consultancy fees or has a financial relationship with Alkermes, Lundbeck, Lundbeck/Otsuka, and Servier. S.W. has sat on an advisory board for Sunovion, Allergan and has received speaker fees from Astra Zeneca. A.H.Y. has received honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen. A.J.C. has received honoraria for speaking from Astra Zeneca, honoraria for consulting with Allergan, Livanova and Lundbeck and research grant support from Lundbeck.
童年期受虐是成年期抑郁症最强的预测因素之一，循环炎症标志物水平的改变是介导风险或恢复力的一种可能机制。
确定童年期受虐对健康个体以及被诊断为重度抑郁症（MDD）的个体循环中41种炎症标志物水平的影响。
我们使用应用于血清的多重电化学发光方法，调查了164例MDD患者和301名对照这两组中童年期受虐与41种炎症标志物水平之间的关联。
经过多重检验校正后，童年期受虐与两组中炎症标志物的改变均无关联。体重指数（BMI）对MDD患者的白细胞介素-6和C反应蛋白水平有显著影响。
在我们的研究中，童年期受虐对MDD参与者或对照组的炎症标志物水平均无影响。相反，我们的结果突出了BMI更相关的影响。
D.A.C.和H.W.就职于礼来公司。R.N.已从太阳药业、杨森和灵北获得演讲费用。G.B.已从礼来获得咨询费和资助。R.H.M.-W.已从阿斯利康、百时美施贵宝、赛博onics、礼来、费雷尔、杨森-西拉格、灵北、MyTomorrows、大冢、辉瑞、脉冲、罗氏、施维雅、SPIMACO和太阳药业获得咨询费或存在财务关系。I.M.A.已从阿尔克姆斯、灵北、灵北/大冢和施维雅获得咨询费或存在财务关系。S.W.曾在太阳药业、艾尔建的顾问委员会任职，并从阿斯利康获得演讲费用。A.H.Y.已从阿斯利康、灵北、礼来、太阳药业获得演讲酬金；从艾尔建、力凡诺娃、灵北、太阳药业、杨森获得咨询酬金；并从杨森获得研究资助。A.J.C.已从阿斯利康获得演讲酬金，从艾尔建、力凡诺娃和灵北获得咨询酬金，并从灵北获得研究资助。
